Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach

International Journal of Molecular Medicine

Volumn 29, Issue 5, 2012, Pages 832-840

  Qiao, Bingbing ^a   Wang, Jiajia ^b   Xie, Jianfei ^a   Niu, Ying ^a   Ye, Shaojun ^a   Wan, Qiquan ^a   Ye, Qifa ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Biomarker; Hepatocellular carcinoma; Oxidative stress; Peroxiredoxin 3

Indexed keywords

PEROXIREDOXIN 3;

ARTICLE; DOWN REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; PEROXIREDOXIN III; PROTEOME; PROTEOMICS; RNA, MESSENGER; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84863229925     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.916     Document Type: Article

References (33)

1. Avila MA, Berasain C, Sangro B and Prieto J: New therapies for hepatocellular carcinoma. Oncogene 25: 3866-3884, 2006. (Pubitemid 43980482)
2. Yoo HY, Patt CH, Geschwind JF and Thuluvath PJ: The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 21: 4329-4335, 2003. (Pubitemid 46621808)
3. Llovet JM, Schwartz M and Mazzaferro V: Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 25: 181-200, 2005. (Pubitemid 40781071)
4. Frank R and Hargreaves R: Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2: 566-580, 2003. (Pubitemid 37361748)
5. Li Z, Zhao X, Bai S, et al: Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma. Mol Cell Proteomics 7: 1810-1823, 2008.
6. Wu FX, Wang Q, Zhang ZM, et al: Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization- time-of-flight mass spectroscopy. Cancer Lett 279: 163-170, 2009.
7. Hlavata I, Vrana D, Smerhovsky Z, et al: Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population. Oncol Rep 24: 1347-1353, 2010.
8. Kanmura S, Uto H, Sato Y, et al: The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol 45: 459-467, 2010.
9. Chuthapisith S, Layfield R, Kerr ID, Hughes C and Eremin O: Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int J Oncol 30: 1545-1551, 2007.
10. Jo M, Nishikawa T, Nakajima T, et al: Oxidative stress is closely associated with tumor angiogenesis of hepatocellular carcinoma. J Gastroenterol 46: 809-821, 2011.
11. Trachootham D, Alexandre J and Huang P: Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579-591, 2009.
12. Oberley LW and Buettner GR: Role of superoxide dismutase in cancer: a review. Cancer Res 39: 1141-1149, 1979. (Pubitemid 9183825)
13. McIlwain CC, Townsend DM and Tew KD: Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25: 1639-1648, 2006.
14. Hu YJ and Diamond AM: Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to selenium. Cancer Res 63: 3347-3351, 2003. (Pubitemid 36735893)
15. Csiki I, Yanagisawa K, Haruki N, et al: Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer. Cancer Res 66: 143-150, 2006. (Pubitemid 43166019)
16. Dietz KJ, Horling F, Konig J and Baier M: The function of the chloroplast 2-cysteine peroxiredoxin in peroxide detoxification and its regulation. J Exp Bot 53: 1321-1329, 2002. (Pubitemid 34544052)
17. Song IS, Kim HK, Jeong SH, et al: Mitochondrial peroxiredoxin III is a potential target for cancer therapy. Int J Mol Sci 12: 7163-7185, 2011.
18. Wonsey DR, Zeller KI and Dang CV: The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci USA 99: 6649-6654, 2002. (Pubitemid 34526187)
19. Rabilloud T, Heller M, Gasnier F, et al: Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. J Biol Chem 277: 19396-19401, 2002. (Pubitemid 34967447)
20. Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA and Chae HZ: Overexpression of peroxiredoxin in human breast cancer. Anticancer Res 21: 2085-2090, 2001.
21. Choi JH, Kim TN, Kim S, et al: Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res 22: 3331-3335, 2002. (Pubitemid 36070110)
22. Kinnula VL, Lehtonen S, Sormunen R, et al: Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 196: 316-323, 2002. (Pubitemid 34189421)
23. Dai Z, Yin J, He H, et al: Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines. Proteomics 10: 3789-3799, 2010.
24. Camma C, Schepis F, Orlando A, et al: Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224: 47-54, 2002. (Pubitemid 34680374)
25. Li XQ, Zhang SL, Cai Z, Zhou Y, Ye TM and Chiu JF: Proteomic identification of tumor-associated protein in ovarian serous cystadenocarcinoma. Cancer Lett 275: 109-116, 2009.
26. Basu A, Banerjee H, Rojas H, et al: Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate 71: 755-765, 2011.
27. Liu X, Feng R and Du L: The role of enoyl-CoA hydratase short chain 1 and peroxiredoxin 3 in PP2-induced apoptosis in human breast cancer MCF-7 cells. FEBS Lett 584: 3185-3192, 2010.
28. Kim K, Yu M, Han S, et al: Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis. Oncol Rep 21: 1391-1396, 2009.
29. Wu XY, Fu ZX and Wang XH: Peroxiredoxins in colorectal neoplasms. Histol Histopathol 25: 1297-1303, 2010.
30. Marra M, Sordelli IM, Lombardi A, et al: Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med 9: 171, 2011.
31. Chang TS, Cho CS, Park S, Yu S, Kang SW and Rhee SG: Peroxiredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signaling by mitochondria. J Biol Chem 279: 41975-41984, 2004. (Pubitemid 39313648)
32. Ryter SW, Kim HP, Hoetzel A, et al: Mechanisms of cell death in oxidative stress. Antioxid Redox Signal 9: 49-89, 2007. (Pubitemid 44901874)
33. Spitz DR, Azzam EI, Li JJ and Gius D: Metabolic oxidation/reduction reactions and cellular responses to ionizing radiation: a unifying concept in stress response biology. Cancer Metastasis Rev 23: 311-322, 2004. (Pubitemid 38881814)